Recently, the Department of Health and Human Services (“HHS”) Office of Inspector General (“OIG”) issued its 2019 “Solutions to Reduce Fraud, Waste, and Abuse in HHS Programs: Top Unimplemented Recommendations.” The OIG releases a version of this report each year outlining its top 25 unimplemented recommendations to reduce fraud, waste, and abuse (“FWA”) among HHS programs. This blog post… Read More »
Following a number of drug pricing reforms implemented or proposed in 2018, 2019 likely will bring more action from HHS and Congress to reduce drug prices. Key Points: In 2018, the Administration implemented and proposed several policy changes to reduce drug prices or spending, and Congress passed new legislation prohibiting health plans from preventing pharmacies from informing plan… Read More »
* * * * * This post sponsored by PwC. * * * * * The US health industry is showing signs of modernizing along the lines of tech, retail and hospitality, changes that should benefit consumers and the healthcare system overall. Once thought to operate outside the greater US economy, the industry—with its byzantine payment system, complicated… Read More »
In the current, ever-changing regulatory environment, smaller compliance teams face unique changes. The OIG’s supplemental Compliance Program Guidance[1] published in 2005 states that ‘there is no single “best” hospital compliance program. Some hospital entities are small and may have limited resources to devote to compliance measures; others are affiliated with well-established, large, multi-facility organizations with a widely dispersed… Read More »
The Trump Administration is moving full speed ahead with its proposals under the Blueprint to Lower Drug Prices (the “Blueprint”). Earlier this week, the Centers for Medicare & Medicaid Services (“CMS”) released a proposed rule that would require pharmaceutical manufacturers to disclose the list price of their pharmaceutical products in direct-to-consumer (“DTC”) television ads (the “Proposed Rule”). This comes only a week… Read More »
Do you need a refresher in healthcare finance? Have you recently transitioned roles and could use an overview of the healthcare landscape? Do you have a new member of your team who would benefit from additional training? Join HFMA at the New to Healthcare seminar on Friday, September 21, 2018. The course will take place at Suffolk Law… Read More »
The Massachusetts-Rhode Island Chapter will be hosting its annual New to Healthcare Seminar on Friday, September 21, 2018 at Suffolk Law School. Join us for a great day of healthcare finance basics from leaders in the industry. The day’s topics include: Fundamentals of Healthcare Finance and Reporting (Erik Lynch, BDO USA LLP) Law, Compliance and Regulations (Timothy Hogan,… Read More »
It seems like every week, there are multiple new developments in the 340B Drug Discount Program. In just the last few weeks, we have seen a new Senate hearing, a new GAO Report, a new House hearing, and introduction of more than a dozen new bills in Congress that would impact 340B. To understand where things may be… Read More »
Late last month, Senators Grassley (R-IA), Brown (D-OH), and Blumenthal (D-CT) introduced the Fighting the Opioid Epidemic with Sunshine Act, a bill that would expand Physician Payment Sunshine Act reporting requirements to cover payments and other transfers of value made to advance practice nurses and physician assistants. As indicated in Senator Grassley’s announcement of the bill, the Senators are tying the expansion… Read More »
